Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Nitrobenzoic Acid SCHEMBL5834720 | 1.00 | TDP1 (0.66) | TDP1SRD5A2KMT2AMEN1CES1 | |
| 4-Nitrobenzoic Acid SCHEMBL4976592 | 0.81 | TDP1 (0.66) | TDP1SRD5A2KMT2AMEN1CES1 | |
| Terephthalic Acid SCHEMBL28023943 | 0.81 | TDP1 (1.00) | TDP1SRD5A2KMT2AMEN1CES1 | |
| 4-Nitrobenzoic Acid SCHEMBL43476 | 0.81 | TDP1 (1.00) | TDP1SRD5A2KMT2AMEN1CES1 | |
| 4-Nitrobenzoic Acid SCHEMBL1566327 | 0.79 | TDP1 (0.95) | TDP1SRD5A2KMT2AMEN1CES1 | |
| 4-Nitrobenzoic Acid SCHEMBL17332065 | 0.79 | TDP1 (0.95) | TDP1SRD5A2KMT2AMEN1CES1 | |
| 4-Nitrobenzoic Acid SCHEMBL10439552 | 0.79 | TDP1 (0.95) | TDP1SRD5A2KMT2AMEN1CES1 | |
| 4-Nitrobenzoic Acid SCHEMBL11331124 | 0.79 | TDP1 (0.95) | TDP1SRD5A2KMT2AMEN1CES1 | |
| 4-Nitrobenzoic Acid SCHEMBL7553997 | 0.79 | TDP1 (0.95) | TDP1SRD5A2KMT2AMEN1CES1 | |
| 4-Nitrobenzoic Acid SCHEMBL17332086 | 0.79 | TDP1 (0.95) | TDP1SRD5A2KMT2AMEN1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102003-B2 | Pyrrolotriazine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060014745-A1 | Pyrrolotriazine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014745-A1 | Pyrrolotriazine compounds | ERBB2, ERBB4, EGFR | TDP1 2267/4885SRD5A2 3662/4885KMT2A 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.